Guangzhou LBP Medicine Science & Technology Co Ltd
SSE:688393
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/E
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Valuation Scenarios
If P/E returns to its 3-Year Average (53.2), the stock would be worth ¥-10.82 (144% downside from current price).
| Scenario | P/E Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -121 | ¥24.6 |
0%
|
| 3-Year Average | 53.2 | ¥-10.82 |
-144%
|
| 5-Year Average | 44 | ¥-8.94 |
-136%
|
| Industry Average | 33.5 | ¥-6.81 |
-128%
|
| Country Average | 29.6 | ¥-6.02 |
-124%
|
Forward P/E
Today’s price vs future net income
| Today's Market Cap | Net Income | Forward P/E | ||
|---|---|---|---|---|
|
¥2.6B
|
/ |
Oct 2025
¥-19.1m
|
= |
|
|
¥2.6B
|
/ |
Dec 2025
¥39.7m
|
= |
|
|
¥2.6B
|
/ |
Dec 2026
¥52.9m
|
= |
|
|
¥2.6B
|
/ |
Dec 2027
¥65.2m
|
= |
|
Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.
Peer Comparison
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| CN |
G
|
Guangzhou LBP Medicine Science & Technology Co Ltd
SSE:688393
|
2.3B CNY | -121 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
162.5B USD | 56.9 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
157.7B USD | 24.8 | |
| US |
|
Stryker Corp
NYSE:SYK
|
120.5B USD | 35.1 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
103.9B USD | 22.3 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
85.4B USD | 23.7 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.5B USD | 44.6 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
39.3B EUR | 18.6 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
44.7B USD | 42.8 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.4B USD | 24.2 | |
| US |
|
Resmed Inc
NYSE:RMD
|
31.1B USD | 20.1 |
Market Distribution
| Min | 0 |
| 30th Percentile | 17.1 |
| Median | 29.6 |
| 70th Percentile | 57.7 |
| Max | 43 569.3 |
Other Multiples
Guangzhou LBP Medicine Science & Technology Co Ltd
Glance View
Guangzhou LBP Medicine Science & Technology Co., Ltd. engages in the research and development, production, and sale of in vitro diagnostic reagents and instruments. The company is headquartered in Guangzhou, Guangdong and currently employs 697 full-time employees. The company went IPO on 2020-08-20. The Company’s main products are pathological diagnostic reagents and instruments, covering three major technology platforms for cytological diagnosis, molecular diagnosis and immunodiagnosis, including LBP series, IHC series, PCR series and FISH series, such as integrated slide and dyeing machine, liquid-based cell and microorganism processing, preservation reagents, automatic nucleic acid molecular hybridization instrument, automatic slide processing system and immunochromogenic reagents, etc. Its products are mainly used in pathological diagnosis of tumors. The firm operates its businesses within the domestic market and to overseas markets.
